Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from BerGenBio ASA ( (BRRGF) ) is now available.
Oncoinvent has published promising 12-month data from its Phase 1 study on the use of Radspherin® for treating platinum-sensitive recurrent ovarian cancer, highlighting the treatment’s safety and tolerability. The ongoing Phase 2 study aims to evaluate the efficacy of Radspherin® in improving progression-free survival in patients with peritoneal metastasis from ovarian cancer, potentially impacting the company’s market positioning and offering new hope for stakeholders in the oncology field.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for cancer treatment. Their lead product, Radspherin®, utilizes radium-224 to target micro-metastases post-surgery, offering a modern approach to radiopharmaceuticals without complex biological targeting. The company is actively investigating Radspherin® in clinical trials for ovarian and colorectal cancer, with operations based in Oslo and a listing on the Oslo Stock Exchange.
YTD Price Performance: -88.95%
Average Trading Volume: 537,814
Current Market Cap: NOK241.2M
Learn more about BRRGF stock on TipRanks’ Stock Analysis page.